查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864420

金诺芬市场依适应症、治疗领域、通路、最终用户和剂型划分－2025-2032年全球预测

Auranofin Market by Indication, Therapeutic Class, Distribution Channel, End User, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，金诺芬市场规模将成长至 3.2296 亿美元，复合年增长率为 4.97%。

关键市场统计数据
基准年 2024 2.1899亿美元
预计年份：2025年 2.3002亿美元
预测年份 2032 3.2296亿美元
复合年增长率 (%) 4.97%

金诺芬在肿瘤学和类风湿性关节炎的重新定位表明，跨学科合作为改善治疗研发和疗效提供了机会。

由于其在治疗领域拥有悠久的成功历史，金诺芬（auranofin）因临床疗效的提升和药理机制的日益清晰而重新受到关注。金诺芬最初是为治疗风湿病而研发和上市的，但其潜在的抗癌和免疫调节特性使其作用机制备受瞩目。这种重新定位促使包括临床研究人员、药品目录委员会、生产者和支付方在内的众多相关人员重新评估金诺芬在现代治疗模式中的地位。

随着临床计画的推进，该药物的特性正沿着两条平行路径进行检验：一是其在免疫介导疾病中的持续效用，二是其在肿瘤治疗领域的拓展。这种双轨并行的发展路径促使人们对给药策略、安全性监测以及其相对于其他治疗层级的定位进行新的考虑。同时，不断变化的监管预期和支付方的审查也在影响研发策略和证据产生计画。

整体而言，这些趋势既带来了机会，也带来了挑战。与奥拉诺芬相关的机构必须权衡对强有力的临床检验的需求与实际需要，例如可靠的供应、合理的配送计划以及与临床医生和患者清晰的价值沟通。本导言阐述了为何对奥拉诺芬的重新评估需要在临床、营运和准入等领域进行周密的策略规划。

科学进步、监管政策变化和商业趋势共同作用，重新定义了奥拉诺芬的临床定位和研究设计重点。

金诺芬的市场格局正在经历多重变革，涵盖科学、监管和商业性应用等多个面向。在科学方面，我们对氧化还原生物学、蛋白质稳态和免疫调节的理解不断深入，揭示了金诺芬潜在的作用机制，使其疗效可望超越最初的适应症。这些机制方面的新发现与更先进的生物标记和转化模型的开发相辅相成，共同塑造现代临床项目和假设驱动型试验的设计。

对于重新定位的药物，监管路径也正在进行重要的调整。监管机构越来越鼓励采用适应性试验设计并整合真实世界数据，前提是安全性特征得到充分阐明，这为申办方设定了路径和预期。同时，对获益风险平衡和成本效益的日益重视意味着，证据策略必须从早期阶段就与支付方和临床医生的需求紧密结合。

在商业方面，分销物流、筹资策略和製造商合作关係的变化正在影响研发人员对规模化生产和市场准入的思考。从许可协议到契约製造关係等策略联盟为供应安全提供了保障，而共同研究模式则有助于快速检验新的适应症。这些科学、监管和商业性的综合变化正在重新定义相关人员如何优先考虑投资和分配资源，以支持下一代金诺芬计画。

预计美国将于2025年调整关税，及其对奥拉诺芬供应链韧性、采购成本和临床试验营运的影响

美国计划于2025年调整关税政策，将对包括奥拉诺芬在内的药品供应链产生影响，尤其是从国际采购活性药物成分、包装材料和辅助材料的药品。关税调整将改变製造商和合约合作伙伴的采购经济效益，促使他们重新评估其采购基础、供应商协议和库存策略。这些营运应对措施通常会与增强自身韧性和降低对单一来源依赖的措施同步进行。

临床研究营运也会受到进出口成本波动的影响。原材料和成品关税的增加会影响研究预算和物流，尤其是依赖集中式供应链的多中心研究。申办方可能需要调整出货计画、寻找替代供应商并制定额外的紧急时应对计画，以确保研究按时完成并确保资料完整性。重点，筹资策略的多元化和近岸外包可以降低波动风险，但实施这些策略需要前置作业时间。

最后，采购成本压力可能会影响药品目录的编制决策和医院的采购协议，进而对支付者和医疗服务提供者产生下游影响。因此，考虑扩大和广泛应用金诺芬的机构应将关税相关因素纳入其供应计划、合约谈判和临床营运中，并制定紧急应变计画，以确保医疗服务的连续性和研究的持续性。

关键细分市场分析重点关注奥拉诺芬临床应用的驱动因素，并按适应症、治疗类别、通路和剂量进行市场定位。

细分市场层面的趋势为理解如何在临床和营运环境中评估和部署金诺芬提供了重要的背景资讯。按适应症划分，关注的重点集中在肿瘤学和类风湿性关节炎领域。在肿瘤学领域，重点关注白血病和淋巴瘤患者群体，因为机制证据和类风湿性关节炎，重点在于区分中度和重度疾病状态，并调整对安全性监测和比较证据的预期。

按治疗类别进行细分可以进一步明确其市场定位。奥拉诺芬被归类于更广泛的缓解疾病抗风湿药物（DMARDs）类别中，而DMARDs是金製剂的一个细分领域。这促使人们将其与生物製药、传统DMARDs和标靶合成药物进行比较。这些比较会影响临床试验终点、相关人员经常要求的头对头资料类型，以及支持实际应用的真实世界证据。

不同分销管道的差异对于营运和患者用药都至关重要。医院、线上药局和零售药局的采购週期、库存管理方式以及与患者的接触点各不相同，这些都会影响药品分发策略和临床医生的处方行为。最终用户细分（例如居家医疗机构与医院和专科诊所）也决定了安全有效用药所需的包装、给药便利性和支援服务。最后，剂量强度细分（通常在 3 毫克和 6 毫克之间）为剂量演算法、治疗监测计划和耐受性比较提供了基础。整合这些多层次的细分因素，有助于相关人员改善临床证据产生、供应链和实施策略，从而更好地反映真实的医疗路径。

来自美洲、欧洲、中东和非洲以及亚太地区的区域性洞察凸显了奥拉诺芬临床应用、监管细微差别和准入趋势方面的区域差异

区域差异将影响奥拉诺芬的临床应用、监管预期和供应策略。在美洲，临床开发往往由研究者主导的大型计画和密集的学术机构网络推动，这既有利于快速验证检验，也需要与支付方的证据要求和医院采购的实际考虑高度契合。

在欧洲、中东和非洲地区，各国和各地区的法规结构和报销途径差异显着，导致证据要求和进入时间各不相同。在这一广大区域内运作的相关人员必须应对不同的卫生技术评估流程、多样化的定价趋势以及影响新型疗法或老药新用疗法推广应用的临床实践模式。

亚太地区正经历着独特的驱动因素，包括多个国家临床试验能力的快速扩张、强大的生产能力以及多元化的医保报销环境。这些因素为区域生产伙伴关係、设计完善的临床试验的快速患者招募以及满足多项监管和临床要求的证据整合创造了机会。在所有地区，本地供应链结构、分销合作伙伴以及临床医生教育倡议对于将临床证据转化为可惠及患者的有效治疗方案至关重要。

从公司层面深入了解奥拉诺芬：研发重点、授权和合作活动、生产和供应方式以及差异化策略

企业行动和策略定位对于推动奥拉诺芬计画从概念阶段迈向临床试验和更广泛的应用至关重要。各机构的研发重点不尽相同，有的机构优先进行机制研究和早期临床试验，有的机构则侧重于后期对比研究，以满足临床医生和支付方的证据需求。许可和伙伴关係活动常被用于加速研发或扩大生产和分销能力，而无需完全建立内部基础设施。

生产和供应策略也是企业差异化的领域。一些公司投资于垂直整合，以确保关键活性药物成分的稳定供应，而其他公司则依赖契约製造组织或分散的供应商网络，这些网络可以根据需求变化进行调整。配方、包装和剂量决策不仅影响临床通讯协定，还影响生产批量、库存策略以及产品是否适合分销到医院、零售和居家医疗机构。

竞争优势往往体现在证据基础的品质和针对性、供应承诺的力量以及相关人员参与的有效性。那些积极主动地将临床计画与实际需求结合、确保供应结构稳健、并与临床网络建立合作关係的机构，更有可能保留市场选择权并减少实施过程中的阻力。这些企业层面的选择将决定奥拉诺芬从研究到成为可行治疗方案的路径。

加强奥拉诺芬研发路径、保障供应链、优化试验设计、改善临床可近性的实用建议

产业领导者应采取务实且优先的行动，使科学研究潜力与营运和市场准入的实际情况相契合。首先，应有目的地建立证据策略：申办方应儘早明确对临床医师和付款者最为重要的临床终点和真实世界终点，并设计能够产生适合这些相关人员的比较和转化数据的研究。这有助于减少后续阻力，并在结果积极时支持快速应用于临床实践。

其次，必须将供应链稳健性作为策略重点。各组织应梳理关键供应商，评估单一来源的脆弱性，并在适当情况下制定替代采购或近岸外包计画。这些措施将确保临床项目和患者用品的持续供应，即使在关税和贸易环境不断变化的情况下也是如此。

第三，产品和服务设计必须反映分销和最终用户的需求。包装、给药方案和病患支援服务应根据医院、专科诊所和居家医疗环境进行客製化，以优化依从性和安全性。最后，相关人员应采取合作方式，透过许可、策略联盟和研究人员联盟等途径共用风险、获取专业知识并加速实证实践。优先采取这些行动将提高负责任且可扩展的实施的可能性，并最大限度地减少营运中断。

调查方法结合了有针对性的初步访谈、系统性的二手研究和严谨的三角验证，以检验不同群体和地区的研究结果。

我们的研究途径整合了多方面的证据来源和检验步骤，以确保分析的严谨性和相关性。主要研究包括对临床医生、供应链专业人员、监管顾问和试验主管进行有针对性的保密访谈，以收集有关临床假设、营运限制和证据需求的第一手资讯。这些访谈旨在揭示不同适应症、治疗领域和最终使用环境中的实际障碍和潜在的缓解措施。

二次研究包括对同侪审查文献、监管指导文件、临床试验註册库和上市公司揭露资讯进行系统性回顾，以整合作用机制理解、安全性数据和计画趋势。随后，对一级研究和二次研究的资讯进行三角验证：识别出共同的主题，检验分歧的观点重新置于背景之中，并透过多个独立资讯来源检验关键结论。

在整个研究过程中，我们始终关注细分市场和区域的具体特征，以确保我们的结论能够反映临床适应症、治疗领域、通路、最终用户、剂量和地理等方面的差异。这种多层次的调查方法能够提供实际的见解，让相关人员应用于临床规划、供应决策和策略合作。

临床趋势、政策和供应风险、细分市场机会以及相关人员的行动被整合起来，以得出负责任地推广奥拉诺芬的统一结论。

新出现的证据表明，奥拉诺芬正逐渐成为一种需要临床、监管和营运等多领域协同合作的药物，其定位也需要进一步扩展。在临床方面，奥拉诺芬同时关注肿瘤和类风湿性关节炎，这既凸显了其潜在适应症的广泛性，也强调了製定针对特异性适应症的证据策略的必要性。在营运方面，分销管道和终端用户环境的差异表明，製剂、包装和支援服务将对药物的实际应用产生重大影响。

政策和供应方面的考量同等重要。关税趋势、采购惯例和製造地都会影响大规模部署和持续测试的能力。应对这些因素需要积极主动的供应计划、灵活的采购管道和合约保障措施，以确保即使在贸易和物流波动时期也能获得供应。

整体而言，最有效的因应措施是采取多学科协作的方式。申办方和生产者应使研究设计与营运物流和支付方合作相协调，医疗系统应制定临床路径，以反映剂量、给药途径和证据标准的差异。透过将检验的临床优先事项、稳健的供应链和清晰的相关人员沟通置于战略核心，各机构将能够负责任地推进其金诺芬项目，并将科学潜力转化为切实的患者获益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 越来越多的临床证据表明，金诺芬可用于治疗卵巢和胃癌等肿瘤。
  • 非专利处方药名奥拉诺芬製剂的推出降低了价格并扩大了市场进入。
  • 生技公司与学术机构进行策略合作，研究金诺芬在神经退化性疾病的应用
  • 罕见疾病中奥拉诺芬再利用的监管核准途径和快速核准程序
  • 一项真实世界研究证实了金诺芬作为抗菌药物在仿单标示外使用中的安全性和有效性。
  • 供应链挑战和黄金采购对阿诺芬生产成本和进度的影响
  • 在奥拉诺芬类风湿性关节炎患者的 II 期试验取得正面结果后，投资人兴趣激增。
  • 奈米颗粒製剂技术的进步提高了金诺芬的标靶递送和生物利用度。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按适应症分類的奥拉诺芬市场

  • 肿瘤学
    • 白血病
    • 淋巴瘤
  • 类风湿性关节炎
    • 缓和
    • 严重

9. 按治疗类别分類的奥拉诺芬市场

  • DMARDs
    • 生物製药
    • 传统的
    • 标靶定向药物
  • 黄金製剂

第十章 金诺芬市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 奥拉诺芬市场（以最终用户划分）

  • 居家医疗设施
  • 医院
  • 专科诊所

12. 以剂量强度分類的奥拉诺芬市场

  • 3mg
  • 6mg

第十三章 奥拉诺芬市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 奥拉诺芬市场（依集团划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国奥拉诺芬市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
    • Viatris Inc
    • Amneal Pharmaceuticals LLC
    • Fresenius Kabi AG
    • Aurobindo Pharma Ltd
    • Dr. Reddy's Laboratories Ltd
    • Apotex Inc
    • Hi-Tech Pharmacal Co., Inc
    • Sagent Pharmaceuticals Inc
Product Code: MRR-F97DD5A7D98B

The Auranofin Market is projected to grow by USD 322.96 million at a CAGR of 4.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 218.99 million
Estimated Year [2025] USD 230.02 million
Forecast Year [2032] USD 322.96 million
CAGR (%) 4.97%

Auranofin repositioning across oncology and rheumatoid arthritis signaling cross-disciplinary opportunities to enhance therapeutic development and outcomes

Auranofin has emerged from a longstanding therapeutic history with renewed interest driven by expanding clinical signals and a clearer understanding of its pharmacology. Initially developed and deployed in the context of rheumatologic indications, its mechanisms of action have attracted attention for potential anticancer and immunomodulatory uses. This repositioning has prompted a wide array of stakeholders-clinical investigators, formulary committees, manufacturers, and payers-to reassess where auranofin fits within contemporary treatment frameworks.

As clinical programs evolve, the drug's profile is being examined in parallel pathways: continued relevance in immune-mediated disease and growing exploration within oncology. This dual trajectory has introduced novel considerations around dosing strategies, safety monitoring, and comparative positioning relative to alternative therapeutic classes. At the same time, changes in regulatory expectations and payer scrutiny are influencing development strategies and evidence generation plans.

Taken together, these dynamics create both opportunity and complexity. Organizations engaging with auranofin must balance the demand for robust clinical validation with practical imperatives such as reliable supply, appropriate distribution arrangements, and clear value communication for clinicians and patients. The introduction establishes why auranofin's renewed relevance warrants careful strategic planning across clinical, operational, and access-related domains.

Scientific advances, regulatory shifts, and commercialization trends converging to redefine auranofin's clinical positioning and trial design priorities

The landscape for auranofin is undergoing several transformative shifts that span science, regulation, and commercial execution. On the scientific front, advances in understanding redox biology, protein homeostasis, and immune modulation have clarified plausible mechanisms through which auranofin could exert benefit beyond its original indication. These mechanistic insights have coincided with more sophisticated biomarkers and translational models, which together are shaping the design of contemporary clinical programs and hypothesis-driven trials.

Regulatory pathways have also recalibrated in ways that matter for repositioned drugs. Agencies increasingly encourage adaptive trial designs and real-world evidence integration when safety profiles are well-characterized, creating both pathways and expectations for sponsors. At the same time, heightened attention to benefit-risk balance and cost-effectiveness means that evidentiary strategies must be tightly aligned to payer and clinician needs from an earlier stage.

Commercially, shifts in distribution logistics, sourcing strategies, and manufacturer partnerships are influencing how developers think about scale-up and access. Strategic alliances-ranging from licensing agreements to contract manufacturing relationships-provide routes to secure supply, while collaborative research models enable more rapid validation of new indications. Together, these scientific, regulatory, and commercial inflections are redefining how stakeholders prioritize investments and allocate resources in support of auranofin's next-generation programs.

Anticipated United States tariff adjustments in 2025 and their effects on auranofin supply chain resilience, procurement costs, and clinical trial operations

Changes to tariff policy in the United States in 2025 have implications for pharmaceutical supply chains that extend to drugs like auranofin, particularly where active pharmaceutical ingredients, packaging, or secondary components are sourced internationally. Tariff adjustments can alter procurement economics for manufacturers and contract partners, prompting reassessments of sourcing locations, supplier contracts, and inventory strategies. These operational responses often happen alongside efforts to shore up resilience and reduce exposure to single-source dependencies.

Clinical research operations are also affected by shifts in import/export costs. Increased tariffs on raw materials or finished goods can influence trial budgets and logistics, especially for multicenter studies that rely on centralized supply distribution. Sponsors may need to modify shipment schedules, identify alternative vendors, or engage additional contingency planning to preserve trial timelines and data integrity. Importantly, procurement tactics that emphasize diversification and nearshoring can mitigate volatility but require lead time to implement.

Finally, payers and providers may experience downstream effects, as procurement cost pressures can influence formulary decisions and hospital purchasing agreements. Organizations considering expanded development or wider deployment of auranofin should therefore integrate tariff-related scenarios into supply planning, contract negotiations, and clinical operations so that contingency measures are in place to maintain continuity of care and research momentum.

Key segmentation insights revealing drivers of clinical application and positioning for auranofin across indications, therapy classes, channels, and dosages

Segment-level dynamics provide essential context for how auranofin is being evaluated and deployed in clinical and operational settings. When viewed by indication, the portfolio of interest clusters into oncology and rheumatoid arthritis; within oncology, focused efforts concentrate on leukemia and lymphoma populations where mechanistic rationale and preliminary data suggest potential benefit, while within rheumatoid arthritis attention differentiates between moderate and severe disease states to tailor safety monitoring and comparative evidence expectations.

Therapeutic class segmentation further clarifies positioning. Auranofin sits in the broader class of disease-modifying antirheumatic drugs and in the niche of gold compounds, prompting comparisons to biologics, conventional DMARDs, and targeted synthetic agents. These comparisons influence clinical trial endpoints and the kinds of head-to-head data that stakeholders often request, as well as the profile of real-world evidence that will support adoption in practice.

Distribution channel distinctions matter operationally and for patient access. Hospital pharmacies, online pharmacies, and retail pharmacies each have different procurement cycles, inventory management practices, and patient touchpoints, which in turn shape fulfillment strategies and clinician prescribing behavior. End-user segmentation-distinguishing home care settings from hospitals and specialty clinics-also drives packaging, dosing convenience, and support services that may be necessary for safe and effective use. Finally, dosage strength segmentation, typically between 3mg and 6mg formulations, underpins dosing algorithms, therapeutic monitoring plans, and comparative tolerability discussions. Integrating these layered segments enables stakeholders to make nuanced decisions about clinical evidence generation, supply arrangements, and adoption strategies that reflect real-world care pathways.

Regional insights across Americas, EMEA, and Asia-Pacific that highlight differences in clinical adoption, regulatory nuance, and access dynamics for auranofin

Regional variations shape clinical adoption, regulatory expectations, and supply strategies for auranofin. In the Americas, clinical development tends to be driven by extensive investigator-led programs and a dense network of academic centers, which supports rapid hypothesis testing but also requires strong alignment with payer evidence requirements and practical considerations for hospital procurement.

In Europe, Middle East & Africa, regulatory frameworks and reimbursement pathways vary markedly by country and region, creating a mosaic of evidence needs and access timelines. Stakeholders operating in this broader region must navigate heterogeneous HTA processes, diverse pricing dynamics, and distinct clinical practice patterns that influence how new or repurposed therapies are adopted.

Asia-Pacific exhibits its own set of drivers: rapid expansion of clinical trial capacity in several countries, strong manufacturing capabilities, and varied reimbursement environments. These factors create opportunities for regional manufacturing partnerships, accelerated enrollment for appropriately designed trials, and a need to calibrate evidence packages so they meet multiple regulatory and clinical expectations. Across all regions, local supply chain arrangements, distribution partners, and clinician education initiatives are critical to translating clinical evidence into practical availability for patients.

Company-level insights on R&D focus, licensing and partnership activity, manufacturing and supply approaches, and differentiation strategies around auranofin

Company behavior and strategic positioning are central to how auranofin programs progress from concept to clinic and to broader availability. Research and development focus varies across organizations, with some prioritizing mechanistic exploration and early-phase trials while others emphasize late-stage comparative studies that address clinician and payer evidence needs. Licensing and partnership activity frequently emerge as mechanisms to accelerate development or to expand manufacturing and distribution capabilities without the need for fully internalized infrastructure.

Manufacturing and supply strategies are another area of differentiation. Some companies invest in vertical integration to secure key active pharmaceutical ingredient flows, while others rely on contract manufacturing organizations and distributed supplier networks that can be reconfigured as demand evolves. Decisions about formulation, packaging, and dosage strengths influence not just clinical protocols but also production batch sizes, inventory strategies, and distribution suitability for hospital, retail, or home care settings.

Competitive differentiation often centers on the quality and specificity of the evidence base, the robustness of supply commitments, and the effectiveness of stakeholder engagement. Organizations that proactively align clinical programs with real-world needs, secure resilient supply arrangements, and cultivate collaborative relationships with clinical networks tend to preserve optionality and reduce implementation friction. These corporate-level choices define the trajectory of auranofin from investigational programs to practical therapeutic options.

Actionable recommendations to strengthen development pathways, secure supply chains, refine trial design, and improve clinical access for auranofin

Industry leaders should adopt pragmatic, prioritized actions to align scientific promise with operational and access realities. First, evidence strategies should be purpose-built: sponsors ought to define the clinical and real-world endpoints that matter most to clinicians and payers early, and design trials that generate comparative and translational data suited to those stakeholders. This reduces downstream friction and supports more rapid assimilation into clinical practice when results are positive.

Second, supply chain robustness must be elevated to a strategic priority. Organizations should map critical suppliers, assess single-source vulnerabilities, and develop alternative sourcing or nearshoring plans where appropriate. These steps enable continuity for both clinical programs and patient supply while tariffs and trade dynamics evolve.

Third, distribution and end-user needs must inform product and service design. Packaging, dosing regimens, and patient support services should be tailored to hospitals, specialty clinics, and home care settings to optimize adherence and safety. Finally, stakeholders should pursue collaborative approaches-whether through licensing, strategic partnerships, or investigator consortia-to share risk, access specialized capabilities, and accelerate evidence generation. Prioritizing these actions will improve the likelihood of responsible, scalable adoption and minimize operational disruptions.

Methodology combining targeted primary interviews, structured secondary research, and rigorous triangulation to validate insights across segments and regions

The research approach integrates multiple evidence streams and validation steps to ensure analytic rigor and relevance. Primary research included targeted, confidential interviews with clinicians, supply chain specialists, regulatory advisors, and trial operations leads to capture first-hand perspectives on clinical hypotheses, operational constraints, and evidence needs. These interviews were structured to surface practical barriers and potential mitigations across indications, therapeutic classes, and end-use settings.

Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to synthesize mechanistic understanding, safety data, and programmatic trends. Findings from primary and secondary sources were then subjected to triangulation: convergent themes were identified, divergent viewpoints were traced back to context, and key assertions were tested against multiple independent information points.

Throughout the process, attention was given to segment and regional specificity so that conclusions reflect the differences between clinical indications, therapeutic classes, distribution pathways, end users, and dosage strengths, as well as geographic distinctions. This layered methodology supports actionable insights that stakeholders can apply to clinical planning, supply decisions, and strategic partnerships.

Integrated conclusion synthesizing clinical momentum, policy and supply risks, segmentation opportunities, and stakeholder actions to responsibly advance auranofin

The evidence gathered points to auranofin's evolving role as a candidate for repositioning that demands coordinated attention across clinical, regulatory, and operational domains. Clinically, the dual focus on oncology and rheumatoid arthritis highlights both the breadth of potential applications and the need for indication-specific evidence strategies. Operationally, distribution channel distinctions and end-user settings underscore that formulation, packaging, and support services materially affect real-world usability.

Policy and supply considerations are equally consequential. Tariff dynamics, procurement practices, and manufacturing footprints will influence the feasibility of broad deployment and trial continuity. Responding to these factors requires proactive supply planning, flexible sourcing, and contractual safeguards that preserve access during periods of trade or logistic volatility.

Taken together, the most effective responses will be multidisciplinary: sponsors and manufacturers must coordinate trial design with operational logistics and payer engagement, while health systems should prepare clinical pathways that reflect differences in dosing, administration settings, and evidence thresholds. By centering strategy on validated clinical priorities, resilient supply arrangements, and clear stakeholder communication, organizations can responsibly advance auranofin programs and translate scientific potential into meaningful patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising clinical evidence for auranofin repurposing in oncology indications such as ovarian and gastric cancers
  • 5.2. Emergence of generic auranofin formulations driving price drops and wider market access
  • 5.3. Strategic partnerships between biotech firms and academic centers for auranofin research in neurodegenerative diseases
  • 5.4. Regulatory pathways and expedited approvals for repurposed auranofin in rare disease indications
  • 5.5. Real-world evidence studies highlighting auranofin safety and efficacy in off-label antimicrobial applications
  • 5.6. Supply chain challenges and raw gold sourcing impact on auranofin manufacturing costs and timelines
  • 5.7. Investor interest surge following positive phase II trial results of auranofin in rheumatoid arthritis refractory patients
  • 5.8. Advances in nanoparticle formulations to enhance auranofin targeted delivery and bioavailability profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Auranofin Market, by Indication

  • 8.1. Oncology
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Auranofin Market, by Therapeutic Class

  • 9.1. DMARDS
    • 9.1.1. Biologics
    • 9.1.2. Conventional
    • 9.1.3. Targeted Synthetic
  • 9.2. Gold Compounds

10. Auranofin Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Auranofin Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Auranofin Market, by Dosage Strength

  • 12.1. 3mg
  • 12.2. 6mg

13. Auranofin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Auranofin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Auranofin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd
    • 16.3.2. Sandoz International GmbH
    • 16.3.3. Viatris Inc
    • 16.3.4. Amneal Pharmaceuticals LLC
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Aurobindo Pharma Ltd
    • 16.3.7. Dr. Reddy's Laboratories Ltd
    • 16.3.8. Apotex Inc
    • 16.3.9. Hi-Tech Pharmacal Co., Inc
    • 16.3.10. Sagent Pharmaceuticals Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 301. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 310. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 311. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 312. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 313. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. GCC AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 318. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 355. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 358. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 359. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 360. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 361. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 362. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 363. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 364. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 365. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 366. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 367. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 368. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 369. G7 AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 370. G7 AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 371. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 372. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 373. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 374. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 375. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 376. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)

TABLE